US SEC Trading Suspension Halt Orders — May 11, 2026

Nasdaq delisting determination received May 5, 2026, after bid price < $1.00 for 30 consecutive days post-180-day compliance failure

Planned appeal by May 12, 2026, to stay May 14 suspension, but no assurance of success provided

Intention to pursue reverse stock split as compliance remedy, historically dilutive and volatile for microcaps

Item 3.01 notice of delisting or failure to satisfy listing rule filed May 11, 2026, signaling ongoing Nasdaq scrutiny

Bylaws amended to lower quorum to 1/3 voting power, potentially easing activist or governance challenges amid delisting risk

Quorum provisions unchanged by vote withdrawals, strengthening management control in distress scenarios

Purple's acute bid price failure (30 days < $1) more severe than Allied's unspecified rule breach, relative underperformance

Initial notice Nov 5, 2025, to determination May 5, 2026 (6 months), indicates prolonged price decay

Filing covers multiple items (3.01, 5.03, 7.01, 9.01), suggesting multifaceted compliance and operational issues

No disclosed YoY/QoQ financial trends, insider trades, or capital allocation, implying opaque fundamentals amid suspensions

Materiality 10/10 vs Allied 8/10, highest risk in stream for trading halt

Neutral sentiment vs Purple's negative, potential for less immediate downside

Suspension scheduled May 14, 2026, unless appeal succeeds, risking trading halt and OTC move

Closed < $1.00 for 30 consecutive business days ending May 4, 2026, after 180-day cure period failure

Deadline May 12, 2026, with uncertain outcome despite planned reverse split

Item 3.01 disclosure of listing rule failure, no details on violation or timeline

Bylaws changes (quorum 1/3, adjournment rules) may signal internal instability or shareholder disputes

Absence of financials, ratios, or operational trends post-compliance failure suggests deteriorating health

No reported period-over-period data, insider activity, or forward guidance amid delisting notice

2/2 filings in 1-week period show cluster of Nasdaq enforcements, liquidity erosion risk

Historical precedent shows post-split declines in 70%+ microcaps, dilution concerns

New provisions for >30-day notices or record date changes could delay resolutions

Successful appeal by May 12 could stay May 14 suspension, short-term price rebound potential

Implementation could regain compliance, historical 20-50% pops in similar microcaps pre-split

Lower quorum (1/3 voting power) facilitates quicker shareholder votes, potential for value-unlocking actions

Unbreakable quorum provisions protect against disruptions, aiding turnaround efforts

Pre-appeal volatility on May 12 deadline, low float microcaps often spike 30%+ on news

Delisting to OTC could attract speculative traders if fundamentals improve, undervalued vs Nasdaq peers

Less negative outlook (8/10 materiality) vs Purple, relative outperformance potential

10/10 score flags high conviction trade on resolution, asymmetry for options plays

Monitor for sector contagion relief if one appeals successfully, pair trade longs/shorts

Potential positive regulation FD disclosure hidden in filing, watch for undervalued catalysts

2/2 companies hit with delisting notices in May 2026, bid price failures dominant, signals small-cap weakness post-2025 volatility

Purple's 180-day window (Nov 2025-May 2026) expired without cure, pattern for prolonged sub-$1 trading in consumer/gaming

Allied's quorum reduction to 1/3 amid Item 3.01, common tactic in 40%+ delisting cases to enable splits/votes

0/2 filings disclose YoY/QoQ metrics, insider trades, or ratios, eroding trust and amplifying halt risks for suspension stream

Deadlines cluster May 12-14, 2026, creating time-bound volatility cluster for traders

Mixed across filings (negative Purple, neutral Allied), avg materiality 9/10, implies 50%+ OTC risk without action

Monitor submission by May 12, 2026, for stay of May 14 suspension, potential halt trigger

Trading halt risk on May 14, 2026, unless appealed; watch Nasdaq announcements

Updates on implementation plans post-appeal, historical success rate ~60% for bid price cures

Further clarification on Item 3.01 violation specifics, expected in follow-up filings Q2 2026

Stockholder meeting outcomes under new 1/3 quorum, watch for Q2/Q3 2026 AGMs

No current trades disclosed; monitor Form 4s for buys/sells signaling conviction amid halts

Post-appeal process timeline (typically 30-45 days), decision could extend into June 2026

Additional suspensions in consumer/gaming, pattern if >2 in May 2026 for short basket